PRP for a sore joint usually means paying the clinic yourself

Insurance usually doesn’t pay for joint PRP

Medicare has a narrow rule. PRP may be covered for some wounds that stay open when the person joins an approved study. That rule doesn’t provide national coverage for a PRP shot used in a knee, shoulder, or hip. A regular private insurance company follows its own policy. The phone number is on your card.

I’d want the answer in writing before paying anything.

Ask whether the exam, the shot, and later visits share one price. Find out whether X-rays, other medical pictures, or a brace will cost more. If the clinic proposes more than one shot, ask for the entire schedule and total charge. Don’t count on getting money back unless the plan puts that promise in writing. You can budget for a firm no more easily than a maybe.

A written quote should include every charge

The clinic can price its regenerative options, which are non-surgical shots that medical providers prepare there from your blood. Those staff members check your joint and manage the care. For PRP, a machine separates the blood before a provider puts the chosen layer inside your aching joint or nearby rope-like tissue. Ask QC Kinetix for its current charge. A written quote must list each service, later visit, and separate fee. It also needs rules for changes or canceled visits.

What matters here is simple: price can’t tell you whether PRP will help.

A higher charge doesn’t prove a better result. A lower one might leave out later care. Compare that bill with exercise, medicine, or a brace that insurance may cover. Then weigh the cost against what the clinician expects for your joint. No single choice fits every budget, and nobody can promise relief.

Sources

1. Medicare's national coverage policy covers autologous platelet-rich plasma ONLY for patients with chronic non-healing diabetic, pressure and/or venous wounds, and only within an approved coverage-with-evidence-development clinical study. There is no Medicare national coverage for PRP in osteoarthritis or tendinopathy, which is why these injections are billed to the patient as cash-pay.

   Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2024.

2. The devices used to spin PRP at the point of care are cleared by FDA as clinical centrifuges, product code JQC, a Class I device under 21 CFR 862.2050 - for example the Biomet GPS Platelet Separation Kit (K030555, cleared 2003) and the Harvest SmartPrep2 / SmartPrep Platelet Concentration System (K103340, cleared 2010). That clearance covers the equipment that separates blood. It is not an FDA approval of platelet-rich plasma as a treatment for osteoarthritis, tendinopathy or any other orthopedic condition, and copy must never blur the two.

   U.S. Food and Drug Administration (Center for Devices and Radiological Health) — 510(k) Premarket Notification database and Product Classification: JQC, Centrifuges (Micro, Ultra, Refrigerated) For Clinical Use, 21 CFR 862.2050. FDA accessdata (CDRH device databases), 2003.

3. The 2019 ACR/Arthritis Foundation osteoarthritis guideline makes STRONG recommendations for exercise, weight loss in people with overweight or obesity, self-management programmes, tai chi, cane use, tibiofemoral bracing, topical and oral NSAIDs and intra-articular glucocorticoid injections for knee OA. Its conditional recommendations cover balance exercises, yoga, CBT, acupuncture, thermal modalities, radiofrequency ablation, acetaminophen, duloxetine and tramadol. Anything offered before a course of the strongly recommended options is being offered out of order.

   Kolasinski SL, Neogi T, Hochberg MC, et al. — 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis & Rheumatology, 2020. DOI: 10.1002/art.41142.

4. The OARSI non-surgical management guideline places intra-articular corticosteroids, intra-articular hyaluronic acid and aquatic exercise at Level 1B/Level 2 for KNEE osteoarthritis depending on comorbidity status, and specifically does NOT recommend them for hip or polyarticular osteoarthritis. Oral and transdermal opioids are strongly not recommended and acetaminophen is conditionally not recommended.

   Bannuru RR, Osani MC, Vaysbrot EE, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis and Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

5. The ESSKA-ICRS consensus applied the RAND/UCLA appropriateness method to 216 clinical scenarios for intra-articular PRP in knee OA. Only 84 scenarios (38.9%) were rated appropriate, 9 (4.2%) inappropriate and 123 (56.9%) uncertain. PRP was judged appropriate in patients aged 80 or under with KL grade 0-III osteoarthritis AFTER failed conservative non-injective or injective treatment; it was NOT considered appropriate as a first treatment, nor in KL grade IV (bone-on-bone) osteoarthritis, where 91.7% and 87.5% of scenarios respectively were uncertain.

   Kon E, de Girolamo L, Laver L, et al. — Platelet-rich plasma injections for the management of knee osteoarthritis: The ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12320.